Show simple item record

dc.contributor.authorRodríguez-Osorio, Iria
dc.contributor.authorMena, Álvaro
dc.contributor.authorMeijide, Héctor
dc.contributor.authorMorano, Luis
dc.contributor.authorDelgado, Manuel
dc.contributor.authorCid-Silva, Purificación
dc.contributor.authorMargusino-Framiñán, Luis
dc.contributor.authorPedreira, José D.
dc.contributor.authorCastro-Iglesias, Ángeles
dc.date.accessioned2019-06-17T11:56:23Z
dc.date.available2019-06-17T11:56:23Z
dc.date.issued2019-06-03
dc.identifier.citationRodríguez-Osorio I, Mena Á, Meijide H, et al. Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals. Plos ONE; 14(6): e0217052es_ES
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/2183/23228
dc.descriptionResearch articlees_ES
dc.description.abstract[Abstract] BACKGROUND: Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular carcinoma (HCC). OBJECTIVE: To compare the incidence of liver-related events and mortality between patients aged ≥65 and <65 years. METHODS: Prospective study comparing patients aged ≥65 and <65 years treated with DAAs. The incidence of liver-related events and mortality, and HCC was compared between age groups. RESULTS: Five hundred patients (120 aged ≥65 and 380 aged <65 years) were included. The incidence of liver-related events was 2.62 per 100 patient-years (py) in older and 1.41/100 py in younger patients. All-cause mortality was 3.89 and 1.27/100 py in older and younger patients, respectively. The respective liver-related mortality rates were 1.12 and 0.31/100 py. In patients with cirrhosis (stage F4), all-cause mortality (P = 0.283) and liver-related mortality (P = 0.254) did not differ between groups. All five liver-related deaths were related to multifocal HCC. The incidence of HCC was 1.91 and 1.43 per 100 py in the older and younger groups, respectively (P = 0.747). The diagnosis of HCC was 8 months after the end of treatment. CONCLUSIONS: The incidence of liver-related events and liver-related mortality was low in older people treated with DAAs and was similar to that in younger patients. The extra mortality in people aged ≥65 years treated with DAAs seems to be secondary to non-liver-related causes. These results support the utilization of DAAs in patients aged ≥65 years.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; JR17/00028es_ES
dc.language.isoenges_ES
dc.publisherPlos ONEes_ES
dc.relation.urihttps://doi.org/10.1371/journal. pone.0217052es_ES
dc.rightsAtribución 3.0 Españaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.titleLiver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antiviralses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitlePlos ONEes_ES
UDC.volume14es_ES
UDC.issue6es_ES
UDC.startPagee0217052es_ES


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record